

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Benbow, et al.	Group Art Unit: 4131
Serial No.: 10/580,615	Examiner: Shterengarts, Samantha L.
Confirmation No.: 5563	
Filed: May 23, 2007	Attorney Docket No.: PC26084A
For: AMINOPYAZOLE DERIVATIVES AS GSK-3 INHIBITORS	

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION/ELECTION REQUIREMENT UNDER
35 U.S.C. §§ 121 AND 372**

This Election is responsive to the Office Action mailed June 25, 2008. The Office Action, in the form of a restriction requirement, set forth a one month period of time to reply. Accordingly, this Election is being submitted before or on its current due date of July 25, 2008.

In response to this Office Action, consideration of the following remarks is respectfully requested.

REMARKS

Claims 1-11 stand restricted into the following 3 groups:

Group I: Claims 1-5 and 8b (compounds of the formula I);

Group II: Claim 6 (method of inhibiting cdk2, cdk5, and/or GSK-3 activity);

Group II: Claims 7-8a and 10-11 (method of treating a cdk2, cdk5, and/or GSK-3 mediated condition).

In response to the restriction requirement, Applicants hereby provisionally elect Group I and concomitantly, species "benzyl-carbamic acid cis-3-[5-[(2-methyl-2-phenylpropionylamino)-2H-pyrazol-3-yl]-cyclobutyl ester (Example 165)" for examination, with traverse. Applicants believe that Claims 1-5 and 8b read on this elected species.